Literature DB >> 14653845

Epilepsy and pregnancy: lamotrigine as main drug used.

A Sabers1, M Dam, B A-Rogvi-Hansen, J Boas, P Sidenius, M Laue Friis, J Alving, M Dahl, J Ankerhus, A Mouritzen Dam.   

Abstract

OBJECTIVES: To study the risk of teratogenicity in infants of women with epilepsy.
MATERIAL AND METHODS: Prospective data from 1996 to 2000 comprised 147 pregnancies. The most frequent antiepileptic drugs (AEDs) used were lamotrigine (LTG) 35% (n = 51), oxcarbazepine (OXC) 25% (n = 37) and valproate (VPA) 20% (n = 30). Seventy-four per cent (n = 109) received monotherapy. Folic acid supplementation was taken during first trimester by 118 patients (80%).
RESULTS: The overall risk of malformations among newborns in the AED-exposed group was 3.1% (n = 4). Two children were born with multiple malformations (VPA monotherapy), two children had ventricular septal defects (one OXC monotherapy, and one OXC and LTG). The risk of malformations was 2.0% in women treated with LTG and 6.7% in women treated with VPA (NS).
CONCLUSION: Despite the small number of cases in the study these data indicate that treatment with LTG during pregnancy might be relatively safe. Larger prospective studies are needed to obtain adequate power for statistical analysis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14653845     DOI: 10.1034/j.1600-0404.2003.00200.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  23 in total

1.  Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register.

Authors:  J Morrow; A Russell; E Guthrie; L Parsons; I Robertson; R Waddell; B Irwin; R C McGivern; P J Morrison; J Craig
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09-12       Impact factor: 10.154

2.  The importance of increased clearance of lamotrigine during pregnancy.

Authors:  Elinor Ben-Menachem
Journal:  Epilepsy Curr       Date:  2005 Mar-Apr       Impact factor: 7.500

3.  Using current evidence in selecting antiepileptic drugs for use during pregnancy.

Authors:  Page B Pennell
Journal:  Epilepsy Curr       Date:  2005 Mar-Apr       Impact factor: 7.500

4.  Use of antiepileptic medications in pregnancy in relation to risks of birth defects.

Authors:  Martha M Werler; Katherine A Ahrens; Jaclyn L F Bosco; Allen A Mitchell; Marlene T Anderka; Suzanne M Gilboa; Lewis B Holmes
Journal:  Ann Epidemiol       Date:  2011-11       Impact factor: 3.797

Review 5.  Treating mood disorders during pregnancy: safety considerations.

Authors:  Malin Eberhard-Gran; Anne Eskild; Stein Opjordsmoen
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 6.  Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors:  Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal:  J Clin Psychopharmacol       Date:  2014-04       Impact factor: 3.153

7.  Alteration of bioelectrically-controlled processes in the embryo: a teratogenic mechanism for anticonvulsants.

Authors:  Sonia Hernández-Díaz; Michael Levin
Journal:  Reprod Toxicol       Date:  2014-05-06       Impact factor: 3.143

Review 8.  Pregnancy Outcomes Following In Utero Exposure to Lamotrigine: A Systematic Review and Meta-Analysis.

Authors:  Gali Pariente; Tom Leibson; Talya Shulman; Thomasin Adams-Webber; Eran Barzilay; Irena Nulman
Journal:  CNS Drugs       Date:  2017-06       Impact factor: 5.749

Review 9.  Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts.

Authors:  Kimford Meador; Matthew W Reynolds; Sheila Crean; Kyle Fahrbach; Corey Probst
Journal:  Epilepsy Res       Date:  2008-06-18       Impact factor: 3.045

Review 10.  Intrauterine exposure to carbamazepine and specific congenital malformations: systematic review and case-control study.

Authors:  Janneke Jentink; Helen Dolk; Maria A Loane; Joan K Morris; Diana Wellesley; Ester Garne; Lolkje de Jong-van den Berg
Journal:  BMJ       Date:  2010-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.